Solutions to mitigate the reverse diffusion of solutes are critical to the successful commercialisation of the fertiliser drawn forward osmosis process. In this study, we proposed to combine a high performance fertiliser (i.e., ammonium sulfate or SOA) with surfactants as additives as an approach to reduce the reverse diffusion of ammonium ions. Results showed that combining SOA with both anionic and non-ionic surfactants can help in reducing the reverse salt diffusion by up to 67%. We hypothesised that, hydrophobic interactions between the surfactant tails and the membrane surface likely constricted membrane pores resulting in increased rejection of ions with large hydrated radii such as SO. By electroneutrality, the rejection of the counter ions (i.e., NH) also therefore subsequently improved. Anionic surfactant was found to further decrease the reverse salt diffusion due to electrostatic repulsions between the surfactant negatively-charged heads and SO. However, when the feed solution contains cations with small hydrated radii (e.g., Na); it was found that NH ions can be substituted in the DS to maintain its electroneutrality and thus the diffusion of NH to the feed solution was increased.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jenvman.2018.08.024 | DOI Listing |
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Florida / Center for Translational Research in Neurodegenerative Disease, Gainesville, FL, USA.
Background: Vaxxinity is developing an active immunotherapy targeting Tau for Alzheimer's disease (AD) and other tauopathies. VXX-301 is a multi-epitope vaccine designed to target the N-terminal and repeat domains of Tau. This design enables targeting multiple forms of Tau thought to contribute to Tau associated pathologies.
View Article and Find Full Text PDFBackground: Impaired Aβ clearance plays a key role in the common, late-onset AD. Anti-Aβ immunotherapies are controversial, in part because of high rates of serious side effects including edema, microhemorrhages, and siderosis, highlighting the importance of the development of alternative Aβ clearance strategy. Here, we introduce a bioinspired nanoparticle named MG-PE3 crossing the human blood-brain barrier (BBB) and clearing Aβ with no adverse effect.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.
View Article and Find Full Text PDFBackground: Small, soluble oligomers, rather than mature fibrils, are the major neurotoxic agents in Alzheimer's disease (AD). In the last few years, Aprile and co-workers designed and purified a single-domain antibody (sdAb), called DesAb-O, with high specificity for Aβ oligomeric conformers. Recently, Cascella and co-workers showed that DesAb-O can selectively detect synthetic Aβ oligomers both in vitro and in cultured cells, neutralizing their associated neuronal dysfunction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!